Novel therapeutic agents for cardiometabolic risk mitigation in heart transplant recipients

Area of Science:

• Cardiology
• Immunology
• Pharmacology

Background:

• Heart transplant (HT) recipients are prone to cardiometabolic diseases.
• Novel therapies like PCSK9 inhibitors, SGLT2 inhibitors, and GLP-1 agonists are common for cardiometabolic risk in the general population.
• Limited data exist on these novel agents' efficacy and safety in the post-HT setting.

Purpose of the Study:

• To review the mechanisms of action of novel pharmacologic agents.
• To explore emerging evidence for their use in heart transplant recipients for cardiometabolic risk mitigation.
• To examine their potential to modulate immune pathways relevant to cardiovascular complications post-transplant.

Main Methods:

• Literature review of novel pharmacologic agents.
• Analysis of mechanisms of action.
• Synthesis of emerging evidence in the context of heart transplantation.
• Review of immunomodulatory effects related to cardiovascular health.

Main Results:

• Novel agents targeting hyperlipidemia, diabetes, and obesity have established roles in general populations.
• Emerging evidence suggests potential benefits for cardiometabolic risk reduction in heart transplant recipients.
• These agents may influence immune pathways implicated in atherogenesis, epicardial adipose tissue, and coronary allograft vasculopathy.

Conclusions:

• Novel pharmacologic agents represent a potential strategy for managing cardiometabolic disease in heart transplant recipients.
• Further clinical studies are warranted to establish safety and efficacy profiles in this specific patient population.
• Understanding the immunomodulatory effects could offer new avenues for preventing transplant complications.